Artificial Intelligence

IBM Halting Sales of Watson AI tool for Cancer and Drug Discovery

Posted on 12 July 2019

The decision to shut down sales of Watson for Drug Discovery marks the highest-profile retreat in the company’s effort to apply artificial intelligence to various areas of health care.

Last year, the company scaled back on the hospital side of its business, and it’s struggled to develop a reliable tool to assist doctors in treating cancer patients.

According to the IEEE Spectrum report, IBM’s entire foray into health care has been marked by the familiar combination of overpromising and under-delivery.

Also last year there was the fiasco of IBM Watson reportedly recommending cancer treatments that were ‘unsafe and incorrect’

Several studies have compared Watson for Oncology’s cancer treatment recommendations to those of hospital oncologists. The concordance percentages indicate how often Watson’s advice matched the experts’ treatment plans.
Sources: Journal of Clinical Oncology 2017Cancer Research 2017JCO Clinical Cancer Informatics 2018

Featured in This Post

Never Miss a Breakthrough!

Sign up for our newletter and get the latest breakthroughs direct to your inbox.

Copyright © Gowing Life Limited, 2023 • All rights reserved • Registered in England & Wales No. 11774353 • Registered office: Ivy Business Centre, Crown Street, Manchester, M35 9BG.